Christopher Peetz - 10 May 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: MIRM
Reported as of: 10 May 2024
Net transaction value: +$17,195
SEC form: 4
Accepted by SEC: 16 May 2024, 16:30:45 UTC
Prior SEC filing: 05 Feb 2024
Next SEC filing: 20 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Christopher Peetz filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 16 May 2024.

Key facts

This page summarizes Christopher Peetz's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 May 2024, 16:30.

Change

Previous filing in this sequence was filed on 05 Feb 2024.
Current net transaction value: +$17,195.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Award

Transaction value: $17,195
Shares: +817
Change %: +0.89%
Price: $21.05
Shares after: 92,770
Date: 10 May 2024
Ownership: Direct
Footnotes: F1

MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 208,570
Date: 10 May 2024
Ownership: By The Peetz Family Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This Form 4 is being filed voluntarily to report the acquisition of 817 shares by the Reporting Person on May 10, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.